Applied Genomics
Genomic scientists in the biopharmaceutical industry seek to use the information and technologies associated with the Human Genome Project to better understand disease, identify new opportunities for therapeutic interventions and enhance the efficiency of drug discovery and development.
“We are committed to being at the forefront of this technology revolution and applying these new approaches as intelligently as possible to help drive drug discovery at Bristol-Myers Squibb, and help patients prevail over serious disease,” says Christopher Miller, Ph.D., director, Functional Genomics.
At Bristol-Myers Squibb, we have successfully used genetic and chemogenomic screens, and target class bioinformatic mining approaches, to identify new candidate drug targets that are now the focus of drug discovery efforts in various disease areas. We have developed high-content cellular assays that allow us to uncover new biological mechanisms of action for genes and small molecules. We use mRNA expression profiling to identify small molecule compounds with highly selective mechanisms of action and activity profiles. We’ve also developed new tools to regulate expression of RNAi molecules. These are all new capabilities that are enhancing drug discovery at Bristol-Myers Squibb.
We work with exciting new technologies like high-throughput gene chips, RNA interference, high-content screening, lentiviral-gene delivery and novel data mining and analysis methods.
We value teamwork and collaboration to ensure that these technologies are maximally aligned with our disease area needs and have the greatest possible impact. We are looking for people who have a background in cell or molecular biology, genomics or proteomics, genetics, bioinformatics and drug discovery, and who are interested in applying cutting edge genomic technologies to develop breakthrough therapeutics.